WntResearch: Limited clinical effects from initial phase 2 results - Redeye

Redeye provides a brief comment on WntResearch’s initial phase 2 data. The results indicate that Foxy-5 has a good safety profile; however, it has limited clinical effects. Consequently, the company has decided to halt further recruitment and intends to terminate the ongoing study. We expect the company’s share to take a significant hit today. Furthermore, we will return with a longer note after the company’s live interview at 11:15 CET.

Länk till analysen i sin helhet: https://www.redeye.se/research/1039841/wntresearch-limited-clinical-effects-from-initial-phase-2-results?utm_source=finwire&utm_medium=RSS